摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-1-methoxymethyl-2-methyl-propylamine hydrochloride | 175458-86-3

中文名称
——
中文别名
——
英文名称
(R)-1-methoxymethyl-2-methyl-propylamine hydrochloride
英文别名
(2R)-1-methoxy-3-methylbutan-2-amine;hydrochloride
(R)-1-methoxymethyl-2-methyl-propylamine hydrochloride化学式
CAS
175458-86-3
化学式
C6H15NO*ClH
mdl
——
分子量
153.652
InChiKey
MELMFNVCMMMNKN-RGMNGODLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.04
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF
    申请人:Bayer Aktiengesellschaft
    公开号:US20190263805A1
    公开(公告)日:2019-08-29
    The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    本申请涉及新颖的7-取代的1-芳基喹啉吡啶-3-羧酰胺,其制备方法,其单独或组合使用,用于治疗和/或预防疾病,以及用于生产药物以治疗和/或预防疾病,特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
  • Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists
    申请人:Alcaraz Lilian
    公开号:US20090062259A1
    公开(公告)日:2009-03-05
    The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta adrenoreceptor agonists.
    本发明涉及式(I)的化合物,其制备方法,该方法的中间体化合物以及化合物在制造治疗ARDS、肺气肿、支气管炎、支气管扩张、COPD、哮喘和鼻炎等疾病的药物中的应用。这些化合物是β-肾上腺素受体激动剂。
  • Novel aspartyldipeptide derivatives and sweetener
    申请人:Ajinomoto Co., Inc.
    公开号:EP0691346A1
    公开(公告)日:1996-01-10
    A low-calory sweetener is provided which is highly stable and safe and has a high sweetness potency. This sweetener comprises novel aspartyldipeptide derivatives of the following general formula (1) and their salts:         L-Asp-X-NH-C*HR₁R₂   (1) wherein R₁ represents an alkyl group having from 1 to 6 carbon atoms, or an alkoxymethyl group having from 2 to 7 carbon atoms; R₂ represents a phenyl group, a benzyl group, a cyclohexyl group, or a cyclohexylmethyl group; the structure having the C* atom is of an (S) form when R₁ is an alkyl group but is of an (R) form when R₁ is an alkoxymethyl group; X represents a residue of a D-α-amino acid or DL-α-amino acid, or a residue of a cyclic or acyclic α,α-dialkylamino acid having from 3 to 6 carbon atoms, when R₁ is an alkyl group, but X represents a residue of a D-α-amino acid or DL-α-amino acid, or a residue of a cyclic or acyclic α,α-dialkylamino acid having from 3 to 6 carbon atoms, when R₁ is an alkoxymethyl group; and the bond between L-Asp and X is an α-bond.
    本发明提供了一种低热量甜味剂,它具有高度稳定性和安全性,并具有较高的甜味效力。这种甜味剂包括以下通式(1)的新型天冬二肽衍生物及其盐类: L-Asp-X-NH-C*HR₁R₂ (1) 其中 R₁ 代表具有 1 至 6 个碳原子的烷基,或具有 2 至 7 个碳原子的烷氧基甲基;R₂ 代表苯基、苄基、环己基或环己基甲基;当 R₁ 为烷基时,具有 C* 原子的结构为 (S) 形式,但当 R₁ 为烷氧基甲基时,具有 C* 原子的结构为 (R) 形式;当 R₁ 是烷基时,X 代表 D-α-氨基酸或 DL-α-氨基酸的残余物,或具有 3 至 6 个碳原子的环状或非环状 α,α-二烷基氨基酸的残余物、但当 R₁ 为烷氧基甲基时,X 代表 D-α-氨基酸或 DL-α-氨基酸的残基,或具有 3 至 6 个碳原子的环状或非环状 α,α-二烷基氨基酸的残基;L-Asp 与 X 之间的键为α键。
  • 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
    申请人:Bayer Aktiengesellschaft
    公开号:US10927109B2
    公开(公告)日:2021-02-23
    The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    本申请涉及新型 7-取代 1-芳基啶-3-羧酰胺、其制备工艺、其单独或组合用于治疗和/或预防疾病的用途,以及其用于生产治疗和/或预防疾病,特别是治疗和/或预防心血管疾病和/或肾脏疾病的药物。
  • Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline
    作者:Juliana M. S. Robey、Sanjay Maity、Sarah L. Aleshire、Angshuman Ghosh、Ajay K. Yadaw、Subho Roy、Sarah Jane Mear、Timothy F. Jamison、Gopal Sirasani、Chris H. Senanayake、Rodger W. Stringham、B. Frank Gupton、Kai O. Donsbach、Ryan C. Nelson、Charles S. Shanahan
    DOI:10.1021/acs.oprd.3c00287
    日期:2023.11.17
查看更多